Evrysdi (risdiplam) is an oral SMN2 splicing modifier for spinal muscular atrophy, taken once daily as a 0.75 mg/mL solution constituted from 60 mg powder or, for the 5 mg dose, as a tablet.
M Care Exports supplies Evrysdi (risdiplam), authorised to Roche companies in the EU and UK and distributed in the US by Genentech, to hospital pharmacies, neuromuscular and paediatric neurology units, importers and tender desks in the GCC, Africa and the UK. If you are looking for the 60 mg powder for oral solution or the 5 mg tablet, send the destination, the presentation and the quantity, and we quote per destination.
Risdiplam exporter and bulk supplier from India.
"We need a partner for Evrysdi" is a typical enquiry from a hospital pharmacy that dispenses spinal muscular atrophy (SMA) treatment or from a tender desk. M Care is a merchant-exporter: we quote against your specification and confirm which presentations your destination registers. Evrysdi is two lines. The bottle holds 60 mg of risdiplam as a powder, and a pharmacist or other healthcare provider constitutes it into a 0.75 mg/mL oral solution before dispensing. The tablet is 5 mg and is for patients aged 2 years and older who weigh 20 kg or more. The dose scales with age and weight up to 5 mg a day, so the pack count per patient depends on the child's weight band and on how often the solution is remade. The dry powder is a room-temperature product. Refrigeration starts only once the solution is constituted. The quote therefore turns on presentation, quantity, the registration route in the destination and Incoterms.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Survival of motor neuron 2 (SMN2) splicing modifier, sourced and documented for export.
Evrysdi is a survival of motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy. The US label (Genentech) covers paediatric and adult patients and lists a 60 mg powder for oral solution that gives 0.75 mg/mL once constituted, and 5 mg tablets in bottles of 30. Dosing is once daily by age and weight: 0.15 mg/kg under 2 months, 0.2 mg/kg from 2 months to under 2 years, 0.25 mg/kg from 2 years under 20 kg, and 5 mg from 2 years at 20 kg or more. The EMA page lists Roche Registration GmbH as marketing authorisation holder, authorised on 26 March 2021, for 5q SMA in patients with a clinical diagnosis of SMA type 1, 2 or 3 or with one to four SMN2 copies. The EU product information lists the powder and a 5 mg film-coated tablet. The UK emc SmPC for the powder lists Roche Products Limited, first authorised on 20 May 2021, and notes an alternative film-coated tablet for patients aged 2 years and older who weigh 20 kg or more.
Active ingredient
Risdiplam. Survival of motor neuron 2 (SMN2) splicing modifier.
Forms and strengths
60 mg powder for oral solution (0.75 mg/mL once constituted); 5 mg film-coated tablet.
Indications
Risdiplam is an oral SMN2 splicing modifier for spinal muscular atrophy, supplied as a 60 mg powder constituted to a 0.75 mg/mL solution and as a 5 mg tablet.
Administration
Oral. Powder for oral solution; film-coated tablet.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Buyers are hospital pharmacists, neuromuscular and paediatric neurology units, MoH and hospital tender desks, and licensed importers and distributors in the GCC, Africa and the UK. Typical enquiries read "I'm looking for Evrysdi powder for a hospital pharmacy" or "We need a partner for risdiplam tablets for a tender". SMA is a rare disease. Each destination has its own regulator, for example the Emirates Drug Establishment (EDE) in the UAE, NAFDAC in Nigeria or the MHRA in the UK, and the route for a rare-disease medicine depends on that regulator. M Care Exports confirms the route per enquiry before quoting.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on risdiplam.
Treat the powder and the solution as two different storage problems. The dry powder is kept in its carton at 20 to 25 °C under the US label (excursions 15 to 30 °C), and the EU and UK texts say do not store above 25 °C and keep the bottle tightly closed against moisture. A pharmacist or other healthcare provider constitutes it before dispensing. The US label then gives 64 days in a refrigerator at 2 to 8 °C, in the original amber bottle, upright, never frozen. Both labels allow the family to keep the solution out of the fridge when needed: the US label allows up to 40 °C for a combined total of 5 days, and the UK SmPC allows below 40 °C for no more than 120 hours. A dose drawn into the oral syringe must be taken within 5 minutes or discarded. The oral solution can be given through a nasogastric or gastrostomy tube. For the tablet, the US label and the EU tablet SmPC allow a tablet dispersed in water to go through a nasogastric or gastrostomy tube of 8 French or larger. Check the label of the destination before planning tube-fed patients. The US label advises avoiding MATE substrates such as metformin, and the EU SmPC covers contraception and male fertility.
The documentation pack a regulator actually asks for.
The labels we fetched set storage for the Evrysdi dry powder at 20 to 25 °C in the US text and not above 25 °C in the EU and UK texts. The refrigerated shelf life of 64 days applies only to the solution constituted by the pharmacy, so M Care plans the export lane at controlled room temperature with temperature monitoring, and the refrigeration duty sits with the receiving pharmacy after constitution. The EU product information gives the powder a 2-year shelf life and the tablet 4 years, with the tablet needing no special temperature but protection from moisture. M Care documentation covers batch certificates of analysis, export documents and destination-aligned dossier support where the regulator asks for it. We state the source and status of each line before quoting, and we make no claim about the manufacturer's certifications on its behalf.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
Adjacent lines procurement desks order alongside risdiplam.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for risdiplam.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Risdiplam supply, the specific questions.
What sets the price of Evrysdi for an importer?
We do not publish a price. For an importer, the landed price of Evrysdi depends on the presentation (60 mg powder for oral solution or 5 mg tablet), the quantity, the destination's registration or special-import route, the shipping lane and Incoterms. The dry powder is labelled for room-temperature storage. M Care Exports quotes per destination once we have the presentation, quantity and country.
What is Evrysdi used for?
Evrysdi is an SMN2 splicing modifier for spinal muscular atrophy. The US label covers paediatric and adult patients with SMA. The EMA page names 5q SMA in patients with a clinical diagnosis of SMA type 1, 2 or 3 or with one to four SMN2 copies. We state only the labelled use, and the exact wording follows the destination's own label.
Is Evrysdi syrup the same as the powder for oral solution?
Buyers often type "Evrysdi syrup", but the labels describe a powder for oral solution. Each bottle holds 60 mg of risdiplam as a powder, and a pharmacist or other healthcare provider constitutes it into a 0.75 mg/mL solution before dispensing. The US label gives 64 days refrigerated at 2 to 8 °C for the constituted solution. A 5 mg film-coated tablet also exists for patients aged 2 years and older who weigh 20 kg or more.
How is the Evrysdi dose worked out, and which presentation do I need?
The daily dose is set by age and weight: 0.15 mg/kg under 2 months, 0.2 mg/kg from 2 months to under 2 years, 0.25 mg/kg from 2 years under 20 kg, and 5 mg from 2 years at 20 kg or more. The solution covers every band. The tablet covers only the 5 mg dose. Your pack plan should follow the patient list by weight band, and we confirm the presentations the destination registers.
How does Evrysdi differ from Spinraza on the label?
Both are labelled for SMA and both act on SMN2, but the labels differ in form. Evrysdi is an oral small-molecule splicing modifier taken once daily as a solution or tablet. Spinraza (nusinersen) is an antisense oligonucleotide given by intrathecal injection, with loading doses and then a maintenance dose once every 4 months in the US label. We compare label facts only and do not recommend one over the other. Our nusinersen page has the Spinraza detail.
Is there a generic of Evrysdi, and how do I buy it for my country?
The US, EU and UK regulator pages we checked list the Roche product, distributed in the US by Genentech, and we did not confirm a marketed generic there. Availability in your country depends on its regulator, and a rare-disease medicine may be registered or may need a different import route. M Care Exports confirms the route and the source product per enquiry, so send the destination, the presentation and the quantity.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-11-08.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.